SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-83482"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-83482" > Omega-3 fatty acid ...

  • Freund-Levi, Yvonne,1956-Department of Neurobiology, Caring Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden (författare)

Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease : OmegAD study - A randomized double-blind trial

  • Artikel/kapitelEngelska2006

Förlag, utgivningsår, omfång ...

  • American Medical Association (AMA),2006
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-83482
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-83482URI
  • https://doi.org/10.1001/archneur.63.10.1402DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-74167URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:1943575URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Background: Epidemiologic and animal studies have suggested that dietary fish or fish oil rich in omega-3 fatty acids, for example, docosahexaenoic acid and eicosapentaenoic acid, may prevent Alzheimer disease (AD). Objective: To determine effects of dietary omega-3 fatty acid supplementation on cognitive functions in patients with mild to moderate AD. Design: Randomized, double-blind, placebo-controlled clinical trial. Participants: Two hundred four patients with AD (age range [mean +/- SD], 74 +/- 9 years) whose conditions were stable while receiving acetylcholine esterase inhibitor treatment and who had a Mini-Mental State Examination (MMSE) score of 15 points or more were randomized to daily intake of 1.7 g of docosahexaenoic acid and 0.6 g of eicosapentaenoic acid (omega-3 fatty acid-treated group) or placebo for 6 months, after which all received omega-3 fatty acid supplementation for 6 months more. Main Outcome Measures: The primary outcome was cognition measured with the MMSE and the cognitive portion of the Alzheimer Disease Assessment Scale. The secondary outcome was global function as assessed with the Clinical Dementia Rating Scale; safety and tolerability of omega-3 fatty acid supplementation; and blood pressure determinations. Results: One hundred seventy-four patients fulfilled the trial. At baseline, mean values for the Clinical Dementia Rating Scale, MMSE, and cognitive portion of the Alzheimer Disease Assessment Scale in the 2 randomized groups were similar. At 6 months, the decline in cognitive functions as assessed by the latter 2 scales did not differ between the groups. However, in a subgroup (n=32) with very mild cognitive dysfunction (MMSE > 27 points), a significant (P <.05) reduction in MMSE decline rate was observed in the omega-3 fatty acid-treated group compared with the placebo group. A similar arrest in decline rate was observed between 6 and 12 months in this placebo subgroup when receiving omega-3 fatty acid supplementation. The omega-3 fatty acid treatment was safe and well tolerated. Conclusions: Administration of omega-3 fatty acid in patients with mild to moderate AD did not delay the rate of cognitive decline according to the MMSE or the cognitive portion of the Alzheimer Disease Assessment Scale. However, positive effects were observed in a small group of patients with very mild AD (MMSE > 27 points).

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Eriksdotter-Jonhagen, MariaKarolinska Institutet (författare)
  • Cederholm, TommyKarolinska Institutet,Uppsala universitet,Klinisk nutrition och metabolism,Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University Hospital, Uppsala, Sweden(Swepub:uu)tomce419 (författare)
  • Basun, HansUppsala universitet,Geriatrik,Division of Geriatrics, Uppsala University Hospital, Uppsala, Sweden(Swepub:uu)habas169 (författare)
  • Faxén-Irving, GerdKarolinska Institutet (författare)
  • Garlind, AnitaDepartment of Neurobiology, Caring Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden (författare)
  • Vedin, IngerKarolinska Institutet (författare)
  • Vessby, BengtUppsala universitet,Klinisk nutrition och metabolism,Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University Hospital, Uppsala, Sweden(Swepub:uu)bengvess (författare)
  • Wahlund, Lars-OlofKarolinska Institutet (författare)
  • Palmblad, JanKarolinska Institutet (författare)
  • Karolinska InstitutetDepartment of Neurobiology, Caring Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Archives of Neurology: American Medical Association (AMA)63:10, s. 1402-14080003-99421538-3687

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy